Lipocine (NASDAQ:LPCN) Share Price Passes Above 50-Day Moving Average – Here’s Why

Shares of Lipocine Inc. (NASDAQ:LPCN) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.30 and traded as high as $2.47. Lipocine shares last traded at $2.38, with a volume of 21,514 shares.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Weiss Ratings cut Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a research report on Monday, April 6th. Finally, Wall Street Zen downgraded shares of Lipocine from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $15.00.

Lipocine Price Performance

The stock has a market capitalization of $20.27 million, a P/E ratio of -1.31 and a beta of 0.48. The stock has a fifty day moving average price of $2.30 and a 200 day moving average price of $5.49.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.16 million. Research analysts anticipate that Lipocine Inc. will post -1.91 earnings per share for the current year.

Insider Activity

In related news, Director John W. Higuchi purchased 40,000 shares of the firm’s stock in a transaction dated Tuesday, April 7th. The shares were purchased at an average cost of $2.03 per share, for a total transaction of $81,200.00. Following the completion of the transaction, the director directly owned 203,797 shares in the company, valued at approximately $413,707.91. This represents a 24.42% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Mahesh V. Patel purchased 25,000 shares of the stock in a transaction dated Monday, April 6th. The stock was purchased at an average cost of $2.03 per share, for a total transaction of $50,750.00. Following the completion of the acquisition, the chief executive officer owned 160,679 shares of the company’s stock, valued at approximately $326,178.37. This represents a 18.43% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have bought 213,000 shares of company stock worth $434,600. Company insiders own 6.35% of the company’s stock.

Institutional Trading of Lipocine

Several institutional investors and hedge funds have recently bought and sold shares of the company. Squadron Capital Management LLC purchased a new position in shares of Lipocine during the 4th quarter valued at $4,256,000. Eversept Partners LP bought a new position in shares of Lipocine in the first quarter worth $2,357,000. Diadema Partners LP purchased a new stake in shares of Lipocine in the fourth quarter worth $2,095,000. AIGH Capital Management LLC purchased a new stake in shares of Lipocine in the first quarter worth $1,598,000. Finally, Ikarian Capital LLC bought a new stake in Lipocine during the fourth quarter valued at $1,602,000. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.